Praxis Precision Medicines Inc.: BTIG sees around 130% upside potential for the biotech!

Praxis Precision Medicines (PRAX) is a biopharmaceutical company focused on developing novel therapies for neurological disorders caused by imbalances in the brain's excitatory and inhibitory abilities. The company's primary goal is to provide precise and potentially disease-modifying solutions for patients with severe neurological and psychiatric disorders, for which there are currently limited or inadequate treatment options. Praxis employs proprietary platforms such as the Cerebrum Small Molecule Platform and the Solidus Antisense Oligonucleotide...